Related Experiment Videos
A multiparametric index of platelet in vitro aggregation in cerebrovascular disease
P P Gazzaniga1, P Ferroni, C Mina
1Dipartimento di Medicina Sperimentale, Università di Roma La Sapienza.
Insights
Platelet aggregation is increased in untreated patients with cerebrovascular disease (CVD), including transient ischemic attack and reversible neurological deficit (TIA-RIND) and stroke. Antiplatelet treatment did not significantly alter these aggregation levels in treated patients.
Area of Science:
- Neurology
- Hematology
- Cardiovascular Medicine
Background:
- Cerebrovascular disease (CVD) involves impaired blood flow to the brain.
- Platelet aggregation plays a critical role in thrombotic events associated with CVD.
- Understanding platelet behavior is crucial for managing and preventing cerebrovascular incidents.
Purpose of the Study:
- To investigate in vitro platelet aggregation patterns in patients with different forms of CVD.
- To compare platelet aggregation in untreated and antiplatelet-treated CVD patients.
- To identify potential biomarkers of hyperaggregation in cerebrovascular disease.
Main Methods:
- Multiparametric analysis of in vitro platelet aggregation in 148 patients.
- Assessed primary and secondary aggregation thresholds and maximum aggregation induced by ADP and epinephrine.
- Patients categorized into TIA-RIND or stroke groups, with and without antiplatelet treatment, compared to controls.
- CT scans used for clinical diagnosis confirmation.
Main Results:
- Significant increases in in vitro platelet aggregation observed in 44.4% of untreated TIA-RIND patients and 33.9% of untreated stroke patients.
- Untreated stroke patients exhibited a higher prevalence of very marked hyperaggregation.
- No significant differences in aggregation were found between treated patient groups and controls.
- Collagen- and ristocetin-induced aggregation showed no differences across all groups.
Conclusions:
- Elevated platelet aggregation is a characteristic finding in untreated patients suffering from cerebrovascular disease.
- Hyperaggregation may be more pronounced in completed stroke patients.
- The efficacy of current antiplatelet therapies in modulating in vitro aggregation requires further investigation in this patient cohort.
Abstract:
148 patients with various forms of cerebrovascular disease (CVD) were studied by means of a multiparametric analysis of in vitro platelet aggregation, based on the following six parameters: ADP and epinephrine primary and secondary aggregation thresholds and percent maximum aggregation induced by optimal concentrations of ADP and epinephrine. These patients were assigned to four study groups, according to clinical diagnosis supported by CT scan, of transient ischemic attack and reversible neurological deficit (TIA-RIND), or completed stroke, in the presence or absence respectively of antiplatelet medical treatment at the time of the study. A statistically significant increase of the in vitro platelet aggregation was found in 44.4% of the untreated TIA-RIND patients and in 33.9% of the untreated stroke patients. However this last group showed a higher percentage of very marked hyperaggregation. Differences between the two treated study groups and controls were not significant. No difference was found in collagen- and ristocetin-induced aggregation between the patient groups and the controls.